ZNF655

ZNF655 (VIK-1) is a Krüppel-like C2H2 zinc finger protein that operates as a nucleocytoplasmic transcriptional regulator coordinating cell-cycle progression and proliferative signaling (PMID:15558030, PMID:35927248). It was first defined through its physical interactions: it binds the Vav-1 SH3 domain and, through a separate domain, cyclin-dependent kinase 4 (CDK4), is expressed during G1 phase, and shuttles between nucleus and cytoplasm via functional nuclear localization and export sequences (PMID:15558030). As a sequence-specific transcriptional activator it directly occupies and drives transcription from target promoters, including the AURKA promoter in glioma (PMID:35280721) and, via facilitated nuclear translocation of the MAFF transcription factor, the CCND1 (Cyclin D1) promoter in ovarian cancer (PMID:41088232). ZNF655 also promotes E2F1 occupancy at the CDK1 promoter, placing it upstream of a CDK1-dependent proliferative axis in pancreatic cancer (PMID:35927248). Across multiple tumor types these activities converge on enhanced proliferation and cancer progression, and ZNF655 is itself subject to feedback control as a downstream target of an ANKHD1/LINC00346 circuit in which LINC00346 triggers Staufen1-mediated decay of ZNF655 mRNA (PMID:32464549).

1. 2005 Medium

   Established ZNF655/VIK-1 as a cell-cycle-associated protein by identifying its direct binding partners and its regulated subcellular distribution, framing it as a G1-phase modulator rather than an orphan zinc finger.

   Evidence Yeast two-hybrid screen of a Jurkat cDNA library, Co-IP, nuclear/cytoplasmic shuttling assay, and overexpression/rescue cell-cycle analysis

   PMID:15558030

   Open questions at the time

   • No DNA-binding target or direct transcriptional output identified at this stage
   • Functional consequence of CDK4 binding not mechanistically resolved
   • Endogenous role versus overexpression phenotype not distinguished
2. 2020 Medium

   Placed ZNF655 within a regulatory feedback circuit, showing it both binds the ANKHD1 promoter and is post-transcriptionally controlled by LINC00346 via Staufen1-mediated mRNA decay, demonstrating the gene is itself a regulated node.

   Evidence Luciferase promoter-binding assay, RIP, STAU1 knockdown, and in vivo angiogenesis model in glioma-associated endothelial cells

   PMID:32464549

   Open questions at the time

   • Direct sequence-specific binding of ZNF655 protein to the ANKHD1 promoter not structurally defined
   • Generality of the feedback loop beyond endothelial cells unknown
3. 2022 Medium

   Defined ZNF655 as a direct transcriptional activator by demonstrating promoter occupancy and reporter activation at AURKA, and showed it promotes E2F1 loading at the CDK1 promoter, identifying concrete downstream proliferative effectors.

   Evidence ChIP-qPCR and dual-luciferase reporter assays plus rescue (AURKA in glioma); Co-IP, ChIP, luciferase and CDK1-knockdown rescue (E2F1/CDK1 in pancreatic cancer)

   PMID:35280721 PMID:35927248

   Open questions at the time

   • Consensus DNA-binding motif for ZNF655 not determined
   • Whether ZNF655 binds CDK1 promoter directly or only enables E2F1 recruitment not fully resolved
4. 2025 Medium

   Extended the activation mechanism to a co-factor mode, showing ZNF655 drives CCND1 transcription by facilitating nuclear translocation of MAFF, linking ZNF655 to cyclin D1-dependent proliferation, stemness, and chemoresistance.

   Evidence Nuclear translocation assay, ChIP for MAFF at the CCND1 promoter, and rescue plus xenograft assays in ovarian cancer

   PMID:41088232

   Open questions at the time

   • Mechanism by which ZNF655 promotes MAFF nuclear import not defined
   • Whether ZNF655 itself contacts the CCND1 promoter not established
5. 2025 Low

   Implicated ZNF655 in AKT-axis signaling across malignant and neuroprotective contexts, linking it to AKT and Akt/Nrf2 antioxidant pathway activation, though without a direct binding mechanism.

   Evidence Loss/gain-of-function assays with immunoblotting in multiple myeloma; adenoviral overexpression, pharmacological Akt inhibition, and Nrf2 siRNA in an OGD/R neuronal injury model

   PMID:39491549 PMID:41352639

   Open questions at the time

   • No direct physical link between ZNF655 and AKT or Nrf2 demonstrated
   • Pathway placement inferred from inhibitor/knockdown phenotypes only
   • Single lab per context, not independently confirmed

• The DNA-binding specificity, direct genomic targets, and structural basis by which ZNF655 selects promoters versus acting through partner transcription factors remain unresolved.
• No genome-wide binding map or consensus motif for ZNF655
• Distinction between direct promoter binding and co-factor/translocation roles not systematically tested
• No structural data on the zinc finger array